Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Multimorbidity, Healthy
In brief
The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models. We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.
Key facts
- Study ID
- NCT06431932
- Run by
- Ove Andersen
- People needed
- 60
- Starts
- 2026-03-24
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-05-19
Who can join
Age: 20 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Aged 20-35 years
- suPAR levels <3.5 ng/mL (± 15% corresponding to assay variation)
- Able to cooperate cognitively
- Able to read and understand Danish
- Women of childbearing potential must use effective contraception
You may not qualify if…
- Body weight >100 kg
- Inability to swallow pills
- Pregnant and/or lactating
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules
- Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial
- Presence of known chronic diagnosis
- Active acute illness
- Prescribed medication, except contraceptives
- Previous cancer diagnosis or treatment
- Use of senolytic and other "anti-aging" supplements
- Older patients with multimorbidity:
- Inclusion Criteria:
- At screening #1 during hospital admission:
- Acutely hospitalized medical patient
- Age ≥65 years
- suPAR >5 ng/mL (± 15% corresponding to assay variation)
- Multimorbidity (≥2 chronic diagnoses)
- Able to cooperate cognitively
- Able to read and understand Danish
- At screening #2 28 days after hospital discharge:
- suPAR >5 ng/mL (± 15% corresponding to assay variation)
- Exclusion Criteria:
- At screening #1 during hospital admission:
- Body weight >100 kg
- Inability to swallow pills
Where it is running
- Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre — Hvidovre, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.